ACADIA to Host Conference Call and Webcast on Friday, May 4, 2018, at
8:30 a.m. Eastern Time
SAN DIEGO, Calif.—(BUSINESS WIRE)—May 1, 2018—ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in central nervous system disorders,
today announced that it will report its financial results for the first
quarter ended March 31, 2018 on Friday, May 4, 2018, before the U.S.
financial markets open. ACADIA's management will host a conference call
and webcast on Friday, May 4, 2018, at 8:30 a.m. Eastern Time to discuss
ACADIA’s financial results and operations.
The conference call may be accessed by dialing 844-821-1109 for
participants in the United States or Canada and 830-865-2550 for
international callers (reference passcode 3685527). A telephone replay
of the conference call may be accessed through May 18, 2018 by dialing
855-859-2056 for callers in the United States or Canada and 404-537-3406
for international callers (reference passcode 3685527). The conference
call also will be webcast live on ACADIA’s website, www.acadia-pharm.com
under the investors section and will be archived there until May 18,
2018.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development and
commercialization of innovative medicines that address unmet medical
needs in central nervous system disorders. ACADIA maintains a website at www.acadia-pharm.com
to which we regularly post copies of our press releases as well as
additional information and through which interested parties can
subscribe to receive e-mail alerts.
Forward-Looking Statements
Statements in this press release that are not strictly historical in
nature are forward-looking statements. These statements include but are
not limited to statements related to the progress and timing of ACADIA’s
drug discovery and development programs, and the timing of future events
or announcements. These statements are only predictions based on current
information and expectations and involve a number of risks and
uncertainties. Actual events or results may differ materially from those
projected in any of such statements due to various factors, including
the risks and uncertainties inherent in drug discovery, development,
approval and commercialization. For a discussion of these and other
factors, please refer to ACADIA’s annual report on Form 10-K for the
year ended December 31, 2017 as well as ACADIA’s subsequent filings with
the Securities and Exchange Commission. You are cautioned not to place
undue reliance on these forward-looking statements, which speak only as
of the date hereof. This caution is made under the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. All
forward-looking statements are qualified in their entirety by this
cautionary statement and ACADIA undertakes no obligation to revise or
update this press release to reflect events or circumstances after the
date hereof, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180501005686/en/
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, (858)
558-2871
Investor Relations
[email protected]